A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors

BRAF(V600E) mutation confers a poor prognosis in metastatic colorectal cancer (CRC) despite combinatorial targeted therapies based on the latest understanding of signaling circuitry. To identify parallel resistance mechanisms induced by BRAF–MEK–EGFR co-targeting, we used a high-throughput kinase ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Saenz, Ana, Atreya, Chloe E., Wang, Changjun, Pan, Bo, Dreyer, Courtney A., Brunen, Diede, Prahallad, Anirudh, Muñoz, Denise P., Ramms, Dana J., Burghi, Valeria, Spassov, Danislav S., Fewings, Eleanor, Hwang, Yeonjoo C., Cowdrey, Cynthia, Moelders, Christina, Schwarzer, Cecilia, Wolf, Denise M., Hann, Byron, VandenBerg, Scott R., Shokat, Kevan, Moasser, Mark M., Bernards, René, Gutkind, J. Silvio, van ‘t Veer, Laura J., Coppé, Jean-Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970872/
https://www.ncbi.nlm.nih.gov/pubmed/36759733
http://dx.doi.org/10.1038/s43018-022-00508-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970872/
https://www.ncbi.nlm.nih.gov/pubmed/36759733
http://dx.doi.org/10.1038/s43018-022-00508-5

Ejemplares similares